Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/28252
Title: | Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve MYCN Silencing with Improved Survival |
Authors: | Tagalakis, AD Jayarajan, V Maeshima, R Ho, KH Syed, F Wu, L-P Aldossary, AM Munye, MM Mistry, T Ogunbiyi, OK Sala, A Standing, JF Moghimi, SM Stoker, AW Hart, SL |
Keywords: | MYCN;neuroblastomas;siRNA;tumor-specific delivery;tumors |
Issue Date: | 30-Jun-2021 |
Publisher: | Wiley-VCH |
Citation: | Tagalakis, A.D. et al. (2021) 'Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve MYCN Silencing with Improved Survival', Advanced Functional Materials, 31 (37), 2104843, pp. 1 - 12. doi: 10.1002/adfm.202104843. |
Abstract: | The authors aim to develop siRNA therapeutics for cancer that can be administered systemically to target tumors and retard their growth. The efficacy of systemic delivery of siRNA to tumors with nanoparticles based on lipids or polymers is often compromised by their rapid clearance from the circulation by the liver. Here, multifunctional cationic and anionic siRNA nanoparticle formulations are described, termed receptor-targeted nanocomplexes (RTNs), that comprise peptides for siRNA packaging into nanoparticles and receptor-mediated cell uptake, together with lipids that confer nanoparticles with stealth properties to enhance stability in the circulation, and fusogenic properties to enhance endosomal release within the cell. Intravenous administration of RTNs in mice leads to predominant accumulation in xenograft tumors, with very little detected in the liver, lung, or spleen. Although non-targeted RTNs also enter the tumor, cell uptake appears to be RGD peptide-dependent indicating integrin-mediated uptake. RTNs with siRNA against MYCN (a member of the Myc family of transcription factors) in mice with MYCN-amplified neuroblastoma tumors show significant retardation of xenograft tumor growth and enhanced survival. This study shows that RTN formulations can achieve specific tumor-targeting, with minimal clearance by the liver and so enable delivery of tumor-targeted siRNA therapeutics. |
Description: | Data Availability Statement: Data available on request from the authors. |
URI: | https://bura.brunel.ac.uk/handle/2438/28252 |
DOI: | https://doi.org/10.1002/adfm.202104843 |
ISSN: | 1616-301X |
Other Identifiers: | ORCID iD: Aristides D. Tagalakis https://orcid.org/0000-0002-4610-0803 ORCID iD: Ruhina Maeshima https://orcid.org/0000-0003-1473-9757 ORCID iD: Arturo Sala https://orcid.org/0000-0002-2841-7866 ORCID iD: Stephen L. Hart https://orcid.org/0000-0001-8254-376X 2104843 |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText. pdf | Copyright © 2021 The Authors. Advanced Functional Materials published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | 2.48 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License